Viewing Study NCT05837455



Ignite Creation Date: 2024-05-06 @ 6:55 PM
Last Modification Date: 2024-10-26 @ 2:57 PM
Study NCT ID: NCT05837455
Status: RECRUITING
Last Update Posted: 2024-07-03
First Post: 2023-04-18

Brief Title: NeoTAILOR ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage IIIII ER-positive HER2-negative Breast Cancer
Sponsor: Washington University School of Medicine
Organization: Washington University School of Medicine

Study Overview

Official Title: NeoTAILOR A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage IIIII ER-positive HER2-negative Breast Cancer
Status: RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage IIIII ER-positive HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy with a primary focus on outcomes in Black patients
Detailed Description: Risk category is defined as follows

Low risk

Baseline Ki67 10 OR
Luminal A molecular intrinsic subtype by PAM50
High risk

Non-Luminal A molecular intrinsic subtype by PAM50 OR
In cases of non-diagnostic PAM50 molecular intrinsic subtype patients will enroll in the high-risk group and undergo Week 4 tumor biopsy

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None